1. Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure?
- Author
-
Berardini A, Biagini E, Saia F, Stolfo D, Previtali M, Grigioni F, Pinamonti B, Crimi G, Salvi A, Ferrario M, De Luca A, Gazzoli F, Bacchi Reggiani ML, Raineri C, Sinagra G, and Rapezzi C
- Subjects
- Aged, Cohort Studies, Female, Heart Failure physiopathology, Heart Valve Prosthesis, Humans, Male, Middle Aged, Mitral Valve Insufficiency etiology, Mitral Valve Insufficiency physiopathology, Stroke Volume, Treatment Outcome, Ventricular Remodeling, Heart Failure complications, Heart Failure surgery, Heart Valve Prosthesis Implantation, Mitral Valve Insufficiency surgery
- Abstract
Background: The role of percutaneous mitral valve repair (PMVR) in patients with end-stage heart failure (HF) and functional mitral regurgitation (FMR) is unclear., Methods: Seventy-five consecutive patients with FMR grade≥3+ and severe HF symptoms despite optimal medical therapy and resynchronization therapy underwent PMVR with the MitraClip system (Abbott, Abbott Park, IL, USA) at 3 centers. Clinical evaluation, echocardiography and pro-BNP measurement were performed at baseline and at 6-month., Results: Mean age was 67±11years, logistic EuroSCORE=23±18%, left ventricle ejection fraction (LVEF) 30±9%. In 6 patients (8%) PMVR was performed as a bridge to heart transplant; many patients were dependent from iv diuretics and/or inotropes. Rate of serious adverse in-hospital events was 1.3% (1 patient who died after conversion to cardiac surgery). Sixty-three patients (84%) were discharged with MR≤2+. At 6-month, 4 patients died (5%), 80% had MR≤2+ and 75% were in New York Heart Association class ≤II. Median pro-BNP decreased from 4395pg/ml to 2594pg/ml (p=0.04). There were no significant changes in LV end-diastolic volume (222±75ml vs. 217±79, p=0.19), end-systolic volume (LVESV, 154±66ml vs. 156±69, p=0.54) and LVEF (30±9% vs. 30±12%, p=0.86). Significant reverse remodeling (reduction of LVESV≥10%) was observed in 25%, without apparent association with baseline characteristics. The number of hospitalizations for HF in comparison with the 6months before PMVR were reduced from 1.1±0.8 to 0.3±0.6 (p<0.001)., Conclusions: In extreme risk HF patients with FMR, PMVR improved symptoms and reduced re-hospitalization and pro-BNP levels at 6months, despite the lack of LV reverse remodeling., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF